SCHEMBL7523154

SCHEMBL7523154

FC(F)(F)c1cccc(C(Br)c2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.56
TDO2 P48775 2/20 0.56
ACP3 P15309 3/20 0.54
PNMT P11086 1/20 0.50
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
CES2 O00748 1/20 0.46
OPRM1 P35372 3/20 0.44
OPRD1 P41143 3/20 0.44
OPRK1 P41145 3/20 0.44
OPRL1 P41146 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
XBP1 P17861 1/20 0.44
HTT P42858 1/20 0.44
S1PR3 Q99500 1/20 0.44
MAPK1 P28482 1/20 0.44
EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4429682 0.94 PNMT (0.55) IDO1TDO2ACP3PNMTALDH1A1
SCHEMBL7523008 0.82 ACP3 (0.55) IDO1TDO2ACP3ALDH1A1TSHR
SCHEMBL474177 0.82 PNMT (0.55) IDO1TDO2ACP3PNMTALDH1A1
SCHEMBL30705300 0.82 PNMT (0.55) IDO1TDO2ACP3PNMTALDH1A1
SCHEMBL8376202 0.81 ACP3 (0.58) IDO1TDO2ACP3PNMTALDH1A1
SCHEMBL13357679 0.80 IDO1 (0.59) IDO1TDO2ACP3PNMTALDH1A1
SCHEMBL215226 0.78 PNMT (0.51) IDO1TDO2ACP3PNMTTSHR
SCHEMBL2498815 0.78 PNMT (0.61) IDO1TDO2ACP3PNMTTSHR
SCHEMBL4069772 0.78 PNMT (0.51) IDO1TDO2ACP3PNMTALDH1A1
SCHEMBL15791963 0.78 PNMT (0.51) IDO1TDO2ACP3PNMTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6417213-B2 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-09 US disclosed
US-20020006944-A1 Tricyclic compounds, their production and use OHKAWA SHIGENORI (JP) 2002-01-17 US disclosed
US-6248766-B1 CARDIOVASCULAR DISORDERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-19 US disclosed
EP-0929534-A1 TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS Takeda Pharmaceutical Company Limited (JP) 1999-07-21 EP disclosed
WO-1998013356-A1 TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006944-A1 Tricyclic compounds, their production and use CNR1, PTGER1, PTGDR IDO1 966/4885TDO2 1112/4885ACP3 4506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.